Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Sarcoma 35Osteosarcoma 22Central Nervous System Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Glioblastoma 5Colorectal Neoplasms 5Colonic Neoplasms 5Pancreatic Neoplasms 4Neuroblastoma 4Gliosarcoma 4Glioma 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Astrocytoma 4Wilms Tumor 3Sarcoma, Ewing 3Rhabdomyosarcoma 3Rectal Neoplasms 3Neuroectodermal Tumors, Primitive, Peripheral 3Neoplasms 3Neoplasm Metastasis 3Melanoma 3Esophageal Neoplasms 3Ependymoma 3Desmoplastic Small Round Cell Tumor 3Choroid Plexus Neoplasms 3Carcinoma, Ovarian Epithelial 3

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Adenocarcinoma × Cisplatin × Sarcoma × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡